On August 25, 2026, the broader market displayed robust momentum, with over 4,200 listed stocks advancing, reflecting a broad-based rally. The innovative drug sector emerged as a standout performer, extending its upward trajectory, while gold-related equities faced notable pressure, leading the decline.

In the biopharmaceutical space, IMMUNOTECH-B (06978) attracted attention as its stock price showed strength amid the sector's revival. The renewed interest in innovative drugs was driven by positive sentiment surrounding recent developments and policy support, which bolstered investor confidence in the segment's growth prospects.

Conversely, gold stocks took a hit as market dynamics shifted, with investors rotating away from safe-haven assets. This divergence highlighted a clear preference for risk-on trading, as capital flowed into high-growth sectors like biotech over defensive plays.

Technical indicators also captured investor interest, as the formation of a MACD golden cross signaled potential upward momentum for several stocks. This bullish signal prompted increased buying activity, contributing to the day's positive market breadth and reinforcing the optimistic tone across the trading floor.